ReviewFrontiers in cardiovascular medicine2025
Approach to large thrombus burden in ST-elevation myocardial infarction.
Review in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Beyond Conventional Coronary Aspiration: Advances in Thrombus Management.JACC. Case reports · 2026Article
- Diagnostic Value of D-Dimer in Patients Visiting the Emergency Department with Symptoms of Acute Coronary Syndrome: A Retrospective Observational Study.Open access emergency medicine : OAEM · 2026Article
- Intracoronary thrombus in ST-segment elevation myocardial infarction: Practical management strategies for the interventional cardiologist.Indian heart journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In ST-Elevation Myocardial Infarction (STEMI), Primary Percutaneous Coronary Intervention (PPCI) is the preferred treatment. However, High Thrombus Burden (HTB), defined by extensive thrombus in the Infarct-Related Artery (IRA), particularly with "cut-off" occlusion patterns and large vessel diameter (>3.5 mm), presents a major challenge. Despite the use of effective anticoagulation, glycoprotein IIb/IIIa inhibitors, and Dual Antiplatelet Therapy (DAPT), HTB remains a significant obstacle. It is associated with complications such as no/slow reflow and distal embolization, leading to adverse cardiovascular outcomes. Accurate assessment using angiographic features and MI thrombus grading is essential before choosing a therapeutic strategy. Management options include mechanical thrombectomy, aspiration, parenteral/oral antiplatelets, intracoronary thrombolytics, and stenting approaches like direct stenting. Success depends on tailored, scenario-specific application of these therapies. This review highlights current strategies to manage HTB during PPCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.